# A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors

> **NCT02952989** · PHASE1 · TERMINATED · sponsor: **Seagen Inc.** · enrollment: 47 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Breast Neoplasms
- Urinary Bladder Neoplasm
- Carcinoma, Squamous Cell of Head and Neck
- Colorectal Neoplasms
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** SGN-2FF
- **DRUG:** pembrolizumab

## Key facts

- **NCT ID:** NCT02952989
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-02-23
- **Primary completion:** 2019-06-24
- **Final completion:** 2019-06-24
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** Due to overall benefit/risk profile
- **Last updated:** 2019-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02952989

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02952989, "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02952989. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*